Related Experiment Videos
Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas
D Bartsch1, D W Shevlin, W S Tung
1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Abstract:
The gene encoding the cell-cycle regulatory protein p16, CDKN2, is localized on chromosome band 9p21. CDKN2 is frequently deleted or mutated in a variety of tumor cell lines, including pancreatic cancer cell lines and xenografts, as well as in some primary tumors. We examined 32 primary pancreatic adenocarcinomas for CDKN2 mutations and for loss of heterozygosity of 9p21 sequences to assess the role of CDKN2 in pancreatic carcinogenesis. Single-strand conformation variant analysis (SSCV) and direct sequencing of the variants revealed somatic CDKN2 mutations in 11 of 32 tumors (five frame-shift mutations, five nonsense mutations, and one missense mutation). One tumor appeared to be characterized by homozygous deletion of CDKN2. These results suggest that CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas.
Insights
Mutations in the CDKN2 gene are common in pancreatic cancer, affecting cell-cycle regulation. These findings highlight CDKN2
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CDKN2 gene encodes the p16 cell-cycle regulatory protein and is located on chromosome band 9p21.
- CDKN2 alterations (deletions or mutations) are frequently observed in various tumor cell lines, including those from pancreatic cancer.
- These alterations suggest a potential role for CDKN2 in cancer development.
Purpose of the Study:
- To investigate the frequency and type of CDKN2 mutations in primary pancreatic adenocarcinomas.
- To assess the role of CDKN2 in pancreatic carcinogenesis by examining mutations and loss of heterozygosity at 9p21.
- To determine the significance of CDKN2 alterations in the development and progression of pancreatic cancer.
Main Methods:
- Analysis of 32 primary pancreatic adenocarcinomas.
- Screening for CDKN2 mutations using single-strand conformation variant analysis (SSCV).
- Direct sequencing of identified variants to confirm somatic mutations.
- Evaluation of loss of heterozygosity for 9p21 sequences.
Main Results:
- Somatic CDKN2 mutations were detected in 11 out of 32 (34%) primary pancreatic tumors.
- Mutation types included five frame-shift, five nonsense, and one missense mutation.
- One tumor exhibited homozygous deletion of the CDKN2 gene.
- These genetic alterations indicate significant disruption of the CDKN2 locus in pancreatic cancer.
Conclusions:
- CDKN2 mutations and deletions are prevalent in pancreatic adenocarcinomas.
- These findings underscore the critical role of CDKN2 in the tumorigenesis or tumor progression of pancreatic cancer.
- The study provides evidence for CDKN2 as a key player in a substantial fraction of pancreatic cancer cases.